. The inhibitory effect of the indicated anticoagulants on the thrombin generation due to a platelet preincubation with the tested compounds before contacting the tumor cells. The inhibitory effect is represented as the peak height of the thrombin generation kinetic curve, which was triggered by (A) MDA-MB-231 cells, (B) MV3 melanoma cells or (C) PC-3 prostate cancer cells, respectively. The figure illustrates the mean values of three identical experiments. Asterisks indicate statistical significance: *** p<0.001. Figure S2 . Since the adapted therapeutic concentrations of UFH and tinzaparin cause a complete inhibition of platetlets aggregation, the impact of decreasing concentrations of (A) UFH and (B) tinzaparin were evaluated. For both anticoagulants, diluting the therapeutic concentration to one tenth or even more is associated with a loss to prevent MDA-MB-231 induced platelet aggregation. (C) To exclude a concentration dependency as a possible reason for the inability of fondaparinux to prevent platelets aggregation at the adapted therapeutic concentration, increasing concentrations were evaluated. Duplication of the therapeutic concentration or even higher concentrations (forty-fold) of fondaparinux could not cause an inhibitory effect. Figure S3 . Tube formation assay of EA.hy926 endothelial cells on geltrex matrix and the impact of platelet releasates activated by MV3 melanoma cells and the inhibition by anticoagulants.
